Theravance Biopharma (NASDAQ:TBPH) Issues Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Theravance Biopharma (NASDAQ:TBPH – Get Rating) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.06), Fidelity Earnings reports. During the same period in the previous year, the company earned ($0.80) earnings per share.

Theravance Biopharma Price Performance

Shares of TBPH traded down $0.74 during mid-day trading on Friday, hitting $8.74. 1,175,657 shares of the company traded hands, compared to its average volume of 1,883,140. Theravance Biopharma has a one year low of $6.10 and a one year high of $14.28. The business has a 50-day moving average of $8.99 and a 200 day moving average of $9.30.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on TBPH. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Theravance Biopharma in a research report on Thursday, July 14th. SVB Leerink initiated coverage on shares of Theravance Biopharma in a report on Monday, May 23rd. They set an “outperform” rating and a $12.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Theravance Biopharma currently has a consensus rating of “Hold” and an average target price of $11.75.

Institutional Trading of Theravance Biopharma

Hedge funds have recently modified their holdings of the stock. UBS Group AG grew its stake in shares of Theravance Biopharma by 45.0% during the first quarter. UBS Group AG now owns 3,549 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 1,101 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of Theravance Biopharma by 51.6% during the first quarter. Acadian Asset Management LLC now owns 8,277 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 2,818 shares during the last quarter. Principal Financial Group Inc. acquired a new position in Theravance Biopharma in the first quarter valued at approximately $101,000. Walleye Capital LLC acquired a new position in Theravance Biopharma in the first quarter valued at approximately $361,000. Finally, BNP Paribas Arbitrage SA lifted its holdings in Theravance Biopharma by 61.9% in the first quarter. BNP Paribas Arbitrage SA now owns 124,234 shares of the biopharmaceutical company’s stock valued at $1,188,000 after buying an additional 47,509 shares during the period. 78.14% of the stock is owned by institutional investors.

About Theravance Biopharma

(Get Rating)

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.